title: [Study of drugs against neoplastic metastasis].
abstract: Further progress in the therapy of malignant diseases is expected from the introduction of potent antimetastatic drugs. Surveying of the complex and multi-step behavior of the metastatic process, compounds showing inhibitory action against tumor cell migration may be ranked among the promising antimetastatic agents. Our present study indicate, however, that the antimigratory actions of certain antitumor drugs (doxorubicin, taxol), and inhibitors of signal transduction (PD-98059, LY-294002, SB-203580) are highly dependent on the assay applied (Boyden-chamber, 3D ECM cell culture). It has been proposed that agents interrupting cell-extracellular matrix contacts (hexyldeoxyuridine, borrelidin) and others interfering with the regulatory mechanism of gene translation (rapamycin, ribavirin) could be regarded as leading compounds in the antimetastatic drug development process. Nevertheless, for introducing diagnostically based targeted therapy the forthcoming tasks must include the further elucidation of the molecular mechanisms implicated in the amoeboid and cluster type of cell migration.
authors.affiliation: Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary. ajeney@korb1.sote.hu
authors.forename: András
authors.initials: A
authors.lastname: Jeney
authors.forename: István
authors.initials: I
authors.lastname: Kenessey
authors.forename: Ferenc
authors.initials: F
authors.lastname: Timár
authors.forename: Júlia
authors.initials: J
authors.lastname: Oláh
authors.forename: Gábor
authors.initials: G
authors.lastname: Pogány
authors.forename: István
authors.initials: I
authors.lastname: Babó
authors.forename: Reveka
authors.initials: R
authors.lastname: Harisi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002465:Cell Movement / Q000187:drug effects*; D002867:Chromones / Q000494:pharmacology; D003857:Deoxyuridine / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005233:Fatty Alcohols / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000503:physiopathology*; D017239:Paclitaxel / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D012254:Ribavirin / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D002867:Chromones; D004791:Enzyme Inhibitors; D005233:Fatty Alcohols; D005419:Flavonoids; D007093:Imidazoles; D009025:Morpholines; D011725:Pyridines; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D012254:Ribavirin; C005066:borrelidin; D004317:Doxorubicin; C093642:SB 203580; D017239:Paclitaxel; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; D020123:Sirolimus; D003857:Deoxyuridine